HeXun Biosciences Past Earnings Performance

Past criteria checks 2/6

There is insufficient data on HeXun Biosciences's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Life Sciences Industry Growth	5.5%
Revenue growth rate	214.0%
Return on equity	22.6%
Net Margin	52.5%
Last Earnings Update	30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How HeXun Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TPEX:6986 Revenue, expenses and earnings (TWD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 24	236	124	37	63
31 Mar 24	183	79	35	58
31 Dec 23	131	33	33	53
30 Sep 23	103	13	28	52
30 Jun 23	75	-7	23	51
31 Mar 23	62	-6	19	45
31 Dec 22	49	-5	14	39

Quality Earnings: 6986 has a high level of non-cash earnings.

Growing Profit Margin: 6986 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 6986's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: 6986 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 6986 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.1%).

Return on Equity

High ROE: 6986's Return on Equity (22.6%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/19 08:29
End of Day Share Price	2024/12/19 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

HeXun Biosciences Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution